File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Berberine and Coptidis Rhizoma as novel antineoplastic agents: A review of traditional use and biomedical investigations

TitleBerberine and Coptidis Rhizoma as novel antineoplastic agents: A review of traditional use and biomedical investigations
Authors
KeywordsAntineoplastic agent
Berberine
Chinese medicine
Coptidis Rhizoma
Huanglian
mechanisms of anticancer action
Issue Date2009
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/jethpharm
Citation
Journal Of Ethnopharmacology, 2009, v. 126 n. 1, p. 5-17 How to Cite?
AbstractEthnopharmacological relevance: Coptidis Rhizoma (Huanglian) and its major component, berberine, have drawn extensive attention toward their antineoplastic effects in the recent years. The antineoplastic effects are related to the Chinese Medicine (CM) properties of Huangliang in treating diseases by removing damp-heat and purging fire and counteracting toxicity. Aim of the review: To trace the long history of the traditional use of Huanglian from folk medicines, especially from Chinese medicine, to recent pharmacological studies of Huanglian and berberine, with an emphasis on their antineoplastic effects and the promise as novel antineoplastic agents. Methods: A total of seven databases were extensively searched for literature research. The terms and keywords for searching included Huanglian, berberine, Coptis, Coptidis Rhizoma, anticancer, anti-invasion, antimatastasis and mechanism. The papers including ours with studies on anticancer and mechanism, pharmacology and toxicology of Huanglian and/or berberine were focused. Results: In view of traditional use, the anticancer effects of Huanglian can be ascribed to its CM trait by removing damp-heat, fire and toxicity. From modern biomedical studies, anticancer effects have been demonstrated in both Huanglian and berberine. The underlying molecular mechanisms involve cell-cycle arrest, apoptosis induction and anti-inflammation. Berberine is an essential anticancer compound in Huanglian. In some studies, the use of Huanglian was shown to be more effective and beneficial than the use of berberine alone. The presence of other protoberberine-type alkaloids in Huanglian might give synergistic effects for the anticancer effects. Berberine also demonstrates effects of antiangiogenesis, anti-invasion and anti-metastasis in some cancer cell lines, however, more investigations are required to unravel the underlying mechanisms involved. Conclusions: The modern evidences of treating cancer with Huanglian and berberine have a strong linkage with traditional concept and rules of using Huanglian in CM practice. As anticancer candidates with low toxicity, berberine and its altered structure, as well as Huanglian and its formulae, will attract scientists to pursue the potential anticancer effects and the mechanisms by using technologies of genomics, proteomics and other advanced approaches. On the other hand, relatively few in vivo studies have been conducted on anticancer effects of Huanglian and berberine. The clinical application of berberine or Huanglian as novel cancer therapeutic agents requires in vivo validations and further investigations of their anticancer mechanisms. © 2009 Elsevier Ireland Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/127599
ISSN
2015 Impact Factor: 3.055
2015 SCImago Journal Rankings: 1.156
ISI Accession Number ID
Funding AgencyGrant Number
research council of the University of Hong Kong10400413
University Grants Committee (UGC) of Hong Kong764708M
Pong Ding Yueng Endowment Fund for Education and Research in Chinese-Western Medicine20005274
Government-Matching Grant Scheme20740314
National Program for Key Science and Technology Project for the 11th Five-Year Plan2006BA106A15-4
Department of Science and Technology of P. R. China
Funding Information:

The study was financially Supported by grants from the research council of the University of Hong Kong (Project Code: 10400413), the University Grants Committee (UGC) of Hong Kong (Project Code: 764708M), the Pong Ding Yueng Endowment Fund for Education and Research in Chinese-Western Medicine (Project Code: 20005274) and the Government-Matching Grant Scheme (4th Phase, Project Code: 20740314). This study is also a part of National Program for Key Science and Technology Project for the 11th Five-Year Plan (Project Code: 2006BA106A15-4) Supported by Department of Science and Technology of P. R. China.

References

 

DC FieldValueLanguage
dc.contributor.authorTang, Jen_HK
dc.contributor.authorFeng, Yen_HK
dc.contributor.authorTsao, Sen_HK
dc.contributor.authorWang, Nen_HK
dc.contributor.authorCurtain, Ren_HK
dc.contributor.authorWang, Yen_HK
dc.date.accessioned2010-10-31T13:34:52Z-
dc.date.available2010-10-31T13:34:52Z-
dc.date.issued2009en_HK
dc.identifier.citationJournal Of Ethnopharmacology, 2009, v. 126 n. 1, p. 5-17en_HK
dc.identifier.issn0378-8741en_HK
dc.identifier.urihttp://hdl.handle.net/10722/127599-
dc.description.abstractEthnopharmacological relevance: Coptidis Rhizoma (Huanglian) and its major component, berberine, have drawn extensive attention toward their antineoplastic effects in the recent years. The antineoplastic effects are related to the Chinese Medicine (CM) properties of Huangliang in treating diseases by removing damp-heat and purging fire and counteracting toxicity. Aim of the review: To trace the long history of the traditional use of Huanglian from folk medicines, especially from Chinese medicine, to recent pharmacological studies of Huanglian and berberine, with an emphasis on their antineoplastic effects and the promise as novel antineoplastic agents. Methods: A total of seven databases were extensively searched for literature research. The terms and keywords for searching included Huanglian, berberine, Coptis, Coptidis Rhizoma, anticancer, anti-invasion, antimatastasis and mechanism. The papers including ours with studies on anticancer and mechanism, pharmacology and toxicology of Huanglian and/or berberine were focused. Results: In view of traditional use, the anticancer effects of Huanglian can be ascribed to its CM trait by removing damp-heat, fire and toxicity. From modern biomedical studies, anticancer effects have been demonstrated in both Huanglian and berberine. The underlying molecular mechanisms involve cell-cycle arrest, apoptosis induction and anti-inflammation. Berberine is an essential anticancer compound in Huanglian. In some studies, the use of Huanglian was shown to be more effective and beneficial than the use of berberine alone. The presence of other protoberberine-type alkaloids in Huanglian might give synergistic effects for the anticancer effects. Berberine also demonstrates effects of antiangiogenesis, anti-invasion and anti-metastasis in some cancer cell lines, however, more investigations are required to unravel the underlying mechanisms involved. Conclusions: The modern evidences of treating cancer with Huanglian and berberine have a strong linkage with traditional concept and rules of using Huanglian in CM practice. As anticancer candidates with low toxicity, berberine and its altered structure, as well as Huanglian and its formulae, will attract scientists to pursue the potential anticancer effects and the mechanisms by using technologies of genomics, proteomics and other advanced approaches. On the other hand, relatively few in vivo studies have been conducted on anticancer effects of Huanglian and berberine. The clinical application of berberine or Huanglian as novel cancer therapeutic agents requires in vivo validations and further investigations of their anticancer mechanisms. © 2009 Elsevier Ireland Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/jethpharmen_HK
dc.relation.ispartofJournal of Ethnopharmacologyen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectAntineoplastic agenten_HK
dc.subjectBerberineen_HK
dc.subjectChinese medicineen_HK
dc.subjectCoptidis Rhizomaen_HK
dc.subjectHuanglianen_HK
dc.subjectmechanisms of anticancer actionen_HK
dc.subject.meshAntineoplastic Agents, Phytogenic - adverse effects - pharmacology - therapeutic use-
dc.subject.meshBerberine - adverse effects - pharmacology - therapeutic use-
dc.subject.meshDrugs, Chinese Herbal - adverse effects - pharmacology - therapeutic use-
dc.subject.meshGenomics - methods-
dc.subject.meshMedicine, Chinese Traditional-
dc.titleBerberine and Coptidis Rhizoma as novel antineoplastic agents: A review of traditional use and biomedical investigationsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0378-8741&volume=126&issue=1&spage=5&epage=17&date=2009&atitle=Berberine+and+Coptidis+rhizoma+as+novel+antineoplastic+agents:+A+review+of+traditional+use+and+biomedical+investigations-
dc.identifier.emailFeng, Y: yfeng@hku.hken_HK
dc.identifier.emailTsao, S: gswtsao@hku.hken_HK
dc.identifier.authorityFeng, Y=rp00466en_HK
dc.identifier.authorityTsao, S=rp00399en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1016/j.jep.2009.08.009en_HK
dc.identifier.pmid19686830-
dc.identifier.scopuseid_2-s2.0-70349971732en_HK
dc.identifier.hkuros176202en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-70349971732&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume126en_HK
dc.identifier.issue1en_HK
dc.identifier.spage5en_HK
dc.identifier.epage17en_HK
dc.identifier.isiWOS:000271790800001-
dc.publisher.placeIrelanden_HK
dc.identifier.scopusauthoridTang, J=37023546200en_HK
dc.identifier.scopusauthoridFeng, Y=24467969600en_HK
dc.identifier.scopusauthoridTsao, S=7102813116en_HK
dc.identifier.scopusauthoridWang, N=35072317700en_HK
dc.identifier.scopusauthoridCurtain, R=35740054700en_HK
dc.identifier.scopusauthoridWang, Y=7601509727en_HK
dc.identifier.citeulike5487597-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats